Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia

INTRODUCTION: Acute myeloblastic leukaemia (AML) constitutes the second most common haematological malignancy in the paediatric population. Current treatment regimens are based on the administration of polychemotherapy, combining high doses of cytarabine with anthracyclines and topoisomerase inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz Builes, Mario, Vela Cuenca, María, Fuster Soler, Jose L, Astigarraga, Itziar, Pascual Martínez, Antonia, Vagace Valero, Jose M, Tong, Hoi Y, Valentín Quiroga, Jaime, Fernández Casanova, Lucía, Escudero López, Adela, Sisinni, Luisa, Blanquer, Miguel, Mirones Aguilar, Isabel, González Martínez, Berta, Borobia, Alberto M, Pérez-Martínez, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955478/
https://www.ncbi.nlm.nih.gov/pubmed/31919123
http://dx.doi.org/10.1136/bmjopen-2019-029642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955478/
https://www.ncbi.nlm.nih.gov/pubmed/31919123
http://dx.doi.org/10.1136/bmjopen-2019-029642

Ejemplares similares